Therapeutic Antibodies

Antibody-drug conjugate
#Antibody drug conjugate (ADC) #Collaboration #ProBio #Therapeutic Antibodies

ProBio and AbTis partner on next-generation antibody-drug conjugate

CRDMO ProBio and South Korean biotechnology company AbTis have agreed an exclusive global licensing agreement for the development of antibody-drug conjugates (ADCs).  AbTis will receive exclusive global rights to develop and commercialise a discovery-stage therapeutic antibody asset generated through ProBio’s biologics discovery and development capabilities against an… Read More

#Business & Investment #News

IgG1 monoclonal antibody
#Autoimmune disease #Phase I trial #Therapeutic Antibodies #Viridian Therapeutics

FcRn inhibitor demonstrates sustained IgG reduction in Phase I trial

Viridian Therapeutics has announced positive Phase I trial results for VRDN-008, a half-life extended bifunctional FcRn inhibitor licensed from Paragon Therapeutics.  In the trial, VRDN-008 demonstrated a potential best-in-class pharmacokinetic (PK) and pharmacodynamic (PD) profile with the potential to be dosed every eight weeks.   VRDN-008… Read More

#News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Therapeutic Antibodies

From AI design to experimental validation: The next frontier in antibody discovery

This article is sponsored by GenScript. Integration of artificial intelligence (AI) into antibody drug discovery is occurring in phases, as AI models mature, and developers seek to compress discovery and development timelines. While increasingly iterative and feedback-driven approaches to AI-driven antibody discovery have made the process more efficient,… Read More

#Exclusive Content

Antibodies
#License agreement #Roche #T cell engagers #Therapeutic Antibodies #Zymeworks

Roche licenses Zymeworks’ trispecific T cell engager targeting DLL3

Zymeworks has entered into a global license and collaboration agreement with Roche for the research, development and commercialisation of ZW209, a T cell engager targeting DLL3.  Under the agreement, Zymeworks is eligible to receive an upfront payment of $55 million, a $40 million payment upon initiation of… Read More

#Business & Investment #News

Monoclonal antibody
#Bionyra Pharma #Inflammatory Bowel Disease #Monoclonal antibodies #Phase I trial

Positive Phase I results for long-acting anti-TL1A antibody

Bionyra Pharma has announced positive interim results from its ongoing Phase I first-in-human study of BYN-002 (TL-001), a long-acting anti-TL1A monoclonal antibody that is in development to treat inflammatory bowel disease (IBD) and other TL1A-driven diseases.   The data are being presented in a late-breaking poster at United… Read More

#News

Johnson & Johnson head office
#Crohn's disease #Johnson & Johnson #Monoclonal antibodies #Phase III trial

J&J reports positive results for Tremfya

Johnson & Johnson has reported positive results for its Phase III FUZION study of its Tremfya (guselkumab) therapy for Crohn’s disease.   The findings show that Tremfya maintained or improved fistula remission through 48 weeks in adults with Crohn’s disease. Johnson & Johnson state the findings, which are… Read More

#Editor's Choice #News

Monoclonal antibodies
#Colorectal cancer #GSK #Immunotherapy #Monoclonal antibodies #Oncology #US Food and Drug Administration (FDA)

FDA approves first immunotherapy for advanced rectal cancer

The US Food and Drug Administration (FDA) has granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly).  The approval is for Jemperli used alone in adults with previously untreated stage II or stage III locally advanced rectal cancer.  Patients with locally advanced… Read More

#Cancer Research #News #Regulatory #Trending News

Closed until further notice
#Antibody Fragments #argenx #Biologics #Phase III trial

Argenx discontinues Phase III Sjögren’s disease trial

argenx has revealed that it will discontinue the Phase III UNITY study of Vyvgart Hytrulo (efgartigimod subcutaneous – efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate-to-severe Sjögren’s disease.  The company said the decision is based on the recommendation from an Independent Data Monitoring Committee (IDMC) to stop… Read More

#News

#Biologics #Cell Science #Drug discovery #Stability characterisation

Stop settling for the proxy – Why stability tests for biologics should measure intermolecular interactions directly

In this advertorial, Dr John Stenson from Malvern Panalytical explains why we need to move away from using ‘SLS mode’ on DLS instruments to determine B22 stability values for biologics. Reliable stability data: A growing need Stability testing for biologics is undergoing something of a revolution, with the… Read More

#Exclusive Content

Monoclonal antibodies
#Chronic obstructive pulmonary disease (COPD) #Connect Biopharma #Monoclonal antibodies #Phase II trial

Monoclonal antibody reduces COPD exacerbations in Phase II trial

Connect Biopharma has announced topline results from its global Phase II study evaluating rademikibart, a potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody.  The treatment was assessed as an add-on treatment for acute exacerbations in adult participants with chronic obstructive pulmonary disease (COPD) and type 2 inflammation. … Read More

#News

Novartis
#Monoclonal antibodies #Neurodegenerative disorders #Novartis #Phase III trial

Novartis faces September’s fourth trial disappointment with ALS drug

Novartis has revealed plans to pause development of Lifonebart (VHB937), an experimental monoclonal antibody drug targeting the TREM2 protein to treat neurodegenerative diseases.  The news comes just days after the company announced its Phase III trial of antibody oligonucleotide conjugate (AOC) del-desiran had failed.  VHB937… Read More

#News #Trending News

Heavy-chain-only antibody
#3DEXPERIENCE cloud platform #Affinity maturation #Antibodies #BIOVIA #Deep learning #Webinar

Register now: Antibody affinity maturation through deep learning and mutation analysis

This webinar, hosted by DDW, explores how deep learning and physics-based methods can be combined to improve antibody affinity maturation and epitope mapping using workflows available in BIOVIA Discovery Studio Simulation on the 3DEXPERIENCE cloud platform. Through case studies involving antibody-antigen and nanobody-receptor complexes, the work demonstrates how virtual mutagenesis,… Read More

#News